Catheter Ablation for Recently Diagnosed Paroxysmal Atrial Fibrillation

• Status: Withdrawn
• Trial end date: 2014-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective is to compare the progression of Atrial Fib (AF) burden by continuous monitoring in patients with recently diagnosed paroxysmal AF treated by catheter ablation (PVI) versus anti-arrhythmic drug (AAD) therapy.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Valley Health System
• Collaborator: Biosense Webster, Inc.
• Treatments: Anti-Arrhythmia Agents

Criteria

Inclusion Criteria:

• Patients with recently diagnosed paroxysmal AF who are eligible to receive specific rhythm control therapy

Exclusion Criteria:

• Previous treatment with Class IC or class III AAD

• Previous AF ablation procedure

• Congestive heart failure (NYHA III-IV functional class)

• Left Ventricle ejection fraction less than 35%

• Left atrial diameter > 55mm

• Unwillingness to participate